本文選題：消化性潰瘍　切入點(diǎn)：幽門螺旋桿菌　出處：《中華醫(yī)院感染學(xué)雜志》2017年19期 　論文類型：期刊論文

【摘要】：目的分析雙歧桿菌三聯(lián)活菌膠囊治療消化性胃潰瘍的臨床療效。方法選取醫(yī)院2014年12月-2016年12月收診的幽門螺旋桿菌(Hp)感染消化性胃潰瘍患者593例為研究對象。隨機(jī)分為常規(guī)治療組306例,聯(lián)合治療組287例,常規(guī)治療組采用傳統(tǒng)三聯(lián)療法,聯(lián)合治療組采用雙歧桿菌三聯(lián)活菌膠囊治療。記錄治療前后兩組患者的胃液pH、靜脈血降鈣素原、白細(xì)胞介素8和腫瘤壞死因子α的變化,治療后進(jìn)行胃鏡檢查潰瘍愈合情況并統(tǒng)計(jì)不良反應(yīng),再次進(jìn)行13 C尿素呼氣試驗(yàn)檢測Hp根除率。結(jié)果治療前,兩組胃液pH、靜脈血降鈣素原、白細(xì)胞介素8和腫瘤壞死因子α水平無顯著差異,常規(guī)組治療后胃液pH為(4.62±0.70),顯著低于聯(lián)合治療組(6.37±0.95),靜脈血降鈣素原、白細(xì)胞介素8和腫瘤壞死因子α水平分別為(43.57±14.17)mg/L、(49.29±16.74)μg/L和(38.22±22.06)ng/L顯著高于聯(lián)合治療組(26.76±8.21)mg/L、(24.67±9.48)μg/L和(27.35±12.60)ng/L(P均0.05);常規(guī)治療組治愈率為35.62%顯著低于聯(lián)合治療組60.98%(P0.05);常規(guī)治療組患者的嚴(yán)重不良反應(yīng)發(fā)生率為4.58%顯著高于聯(lián)合治療組2.44%(P0.05);常規(guī)治療組的根除率為38.56%顯著低于聯(lián)合治療組82.23%(P0.05)。結(jié)論使用雙歧桿菌三聯(lián)活菌膠囊治療Hp感染的消化性胃潰瘍,不良反應(yīng)發(fā)生率低,臨床療效和根除率明顯優(yōu)于傳統(tǒng)的三聯(lián)療法。
[Abstract]:Objective to analyze the clinical effect of Bifidobacterium triple active bacilli capsule in the treatment of peptic ulcer. Methods 593 patients with peptic ulcer infected by Helicobacter pylori were selected from December 2014 to December 2016 in our hospital. They were randomly divided into routine treatment group (306 cases), 287 patients in the combined treatment group were treated with traditional triple therapy and the combined treatment group were treated with Bifidobacterium triple viable capsule. The pH of gastric juice and procalcitonin in venous blood were recorded before and after treatment in both groups. The changes of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF- 偽), the ulcer healing and adverse reactions were examined by gastroscopy after treatment, and the HP eradication rate was detected by 13 C urea breath test again. There was no significant difference in pH, procalcitonin, interleukin-8 and tumor necrosis factor 偽 between the two groups. After treatment, the pH of gastric juice in the routine group was 4.62 鹵0.70, which was significantly lower than that in the combined treatment group (6.37 鹵0.95). The levels of interleukin 8 and tumor necrosis factor 偽 were 43.57 鹵14.17 mg / L and 49.29 鹵16.74 渭 g / L and 38.22 鹵22.06 渭 g / L, respectively, which were significantly higher than those in the combined treatment group (26.76 鹵8.21 mg / L, 24.67 鹵9.48) 渭 g / L and 27.35 鹵12.60 ng / L / L, respectively. The cure rate in the routine treatment group was significantly lower than that in the combined treatment group (60.98g / L vs 60.98g / L). The incidence rate of 4.58% was significantly higher than that of the combined treatment group (2.44) and the eradication rate of the routine treatment group was 38.56% significantly lower than that of the combined treatment group (82.23) P0.05.Conclusion the peptic ulcer of HP infection was treated with Bifidobacterium triple live bacillus capsule. The incidence of adverse reactions was low, and the clinical efficacy and eradication rate were significantly better than the traditional triple therapy.
【作者單位】： 佛山市三水區(qū)人民醫(yī)院消化內(nèi)科;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(30271567)
【分類號】：R573.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前9條

1 李君強(qiáng);陳雪清;魏曉楠;王云昭;;安腸方合雙歧桿菌活菌膠囊治療腹瀉型腸易激綜合征34例療效觀察[J];河北中醫(yī);2011年06期

2 朱素平;;雙歧桿菌三聯(lián)活菌膠囊聯(lián)合腸胃康治療腹瀉型腸易激綜合征的療效觀察[J];吉林醫(yī)學(xué);2013年29期

3 張?zhí)鞎?向圓花;;雙歧桿菌三聯(lián)活菌膠囊對肝硬化非感染性腹瀉患者細(xì)胞免疫功能的影響及療效觀察[J];中國現(xiàn)代醫(yī)生;2014年10期

4 路亞楓,王雁;乳酸三聯(lián)活菌膠囊治療急性腹瀉[J];中國新藥與臨床雜志;2000年01期

5 林昱;;帕羅西汀聯(lián)合雙岐三聯(lián)活菌膠囊治療腹瀉型腸易激綜合征療效觀察[J];臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志;2011年07期

6 曾柏倫;王聰;;雙岐三聯(lián)活菌膠囊對慢性乙型肝炎后肝硬化患者肝功能和炎性因子的影響[J];海南醫(yī)學(xué)院學(xué)報;2014年01期

7 傅思武;潘令嘉;周殿元;劉思德;;酪酸梭菌-雙歧桿菌二聯(lián)活菌膠囊對腹瀉的臨床療效觀察[J];臨床消化病雜志;2010年02期

8 梁萬金;黎昌群;;黛力新聯(lián)合三聯(lián)活菌膠囊治療腹瀉型腸易激綜合征36例臨床觀察[J];西南軍醫(yī);2010年05期

9 姚春美;;雙歧桿菌三聯(lián)活菌膠囊治療乙肝后肝硬化失代償期伴腸功能紊亂臨床觀察[J];中國鄉(xiāng)村醫(yī)藥;2014年12期

，

本文編號：1590876